Holy Stone Healthcare Co., Ltd. (TPEX: 4194)
Health Care · Biotechnology · TW
NT$6.02
-4.14% today · -45.8% 1Y
Holy Stone Healthcare Co., Ltd. (TPEX: 4194) operates in the Biotechnology industry within the Health Care sector. The company is valued at $27.60M and employs 309 people.
Over the last twelve months the share price has lost 45.8%, trading between 5.90 and 11.65.
Tweenvest scores Holy Stone Healthcare Co., Ltd. across four factors: quality 27/100. Its strongest factor is quality.
4194 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $27.60M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.87
- Dividend yield
- —
- Beta (5Y)
- 0.69
- 52-week high
- NT$11.65
- 52-week low
- NT$5.90
- Avg volume (3M)
- —
- Shares outstanding
- 145.97M
- Employees
- 309
- Next earnings
- —
About Holy Stone Healthcare Co., Ltd.
Holy Stone Healthcare Co., Ltd., together with its subsidiaries, develops and sells hyaluronic acid-related therapeutic products in Taiwan. The company offers RenehaVis and SportVis, which are injectable medical devices for osteoarthritis and soft tissue injuries; TRUD, a medical device that contains a mixture of hyaluronic acid used for the treatment and prevention of ulcerative colitis in inflammatory bowel disease (IBD); and GAF, a gel for anal fissure healing. It also develops IBD98-M, an oral capsule that is in a Phase IIa trial for ulcerative colitis; CA102N, a receptor-targeted chemotherapy that is in a Phase II trial for metastatic colorectal cancer, as well as in a pre-clinical stage for pancreatic ductal adenocarcinoma and a discovery stage for triple-negative breast cancer; ND108E, a CNS-targeted HA conjugate that is in a pre-clinical trial for Alzheimer’s disease; AMD112, a non-invasive HA-conjugated small molecule therapy that is in a pre-clinical trial for wet age-related macular degeneration and other neovascular retinal diseases; and HylCaryo, a hyaluronic acid (HA)-derived nanoparticle platform in a discovery stage. In addition, the company engages in general investment; development and sale of medical devices; biotechnology services; and patent application for pharmaceutical products. Holy Stone Healthcare Co., Ltd. was founded in 2001 and is headquartered in Taipei, Taiwan.
- ISIN
- TW0004194006
- Founded
- 2001
- Listed since
- Dec 13, 2013
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.80 | +0.00% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $444.00 | +0.40% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.10 | -0.45% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $551.33 | -0.27% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €903.40 | +2.75% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $155.51 | -2.09% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.